Signals
5Lung cancer screening pathway integration matures
Low-dose CT screening adoption growth, AI-assisted nodule management, blood-based biomarker integration, and primary-care pathway formalisation are restructuring lung cancer screening.
Soft tissue sarcoma therapy widens around fusion-defined biomarkers
NTRK inhibitor cross-tumour use, GIST line-of-therapy expansion, and emerging mechanism-targeted programs are reshaping soft tissue sarcoma management.
Colorectal cancer third-line and KRAS-targeted options widen
KRAS G12C-targeted programs, fruquintinib third-line use, and trastuzumab deruxtecan in HER2-amplified colorectal are restructuring late-line colorectal cancer.
Gastric and gastroesophageal cancer therapy reshapes around HER2 maturity and claudin18.2 entry
Trastuzumab deruxtecan in HER2-low gastric, claudin18.2-targeted zolbetuximab approval, and IO combinations are restructuring upper GI oncology.
Hepatocellular carcinoma systemic therapy options mature
Atezolizumab plus bevacizumab maturity, durvalumab plus tremelimumab adoption, and TIGIT-class programs are restructuring advanced HCC.
Snapshots
4Thyroid cancer therapy reference (2026)
Reference snapshot of thyroid cancer therapy across differentiated, medullary, and anaplastic subtypes.
Cholangiocarcinoma therapy reference (2026)
Reference snapshot of cholangiocarcinoma therapy across resectable and advanced disease and biomarker-defined targeted tiers.
Adult diffuse glioma therapy reference (2026)
Reference snapshot of adult diffuse glioma therapy across IDH-mutant grade 2/3 disease, glioblastoma first-line, and recurrent disease.
Hepatocellular carcinoma therapy reference (2026)
Reference snapshot of HCC therapy across early, intermediate, and advanced disease.
Explained
4What is thyroid cancer?
Plain-language primer on thyroid cancer, why molecular profile now matters, and how modern therapy works.
What is cholangiocarcinoma?
Plain-language primer on cholangiocarcinoma, why molecular profiling now matters so much, and how modern therapy works.
What is glioblastoma?
Plain-language primer on glioblastoma, why it has been so hard to treat, and what is changing in glioma therapy.
What is hepatocellular carcinoma?
Plain-language primer on hepatocellular carcinoma, why it usually develops on a background of liver disease, and how the modern therapy options compare.